Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) 是一种 NMDA 受体调节剂,具有甘氨酸位点部分激动剂性质,有研究抑郁症的潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 662 | 现货 | ||
2 mg | ¥ 1,090 | 现货 | ||
5 mg | ¥ 2,150 | 现货 | ||
10 mg | ¥ 3,150 | 现货 | ||
25 mg | ¥ 5,130 | 现货 | ||
50 mg | ¥ 6,910 | 现货 | ||
100 mg | ¥ 9,480 | 现货 | ||
500 mg | ¥ 18,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,530 | 现货 |
产品描述 | Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. |
体内活性 | Rapastinel Trifluoroacetate, a tetrapeptide (Thr-Pro-Pro-Thr-amide), has been reported to have fast acting antidepressant properties in man based upon its N-methyl-D-aspartate receptor (NMDAR) glycine site functional partial agonism. |
动物实验 | C57BL/6J mice given a single dose or subchronic ketamine (30 mg/kg.i.p.) showed acute or persistent deficits in NOR, respectively.?Acute i.v. rapastinel (1.0 mg/kg), did not induce NOR deficit.?Pre-treatment with Rapastinel Trifluoroacetate?significantly prevented acute ketamine-induced NOR deficit.?Rapastinel Trifluoroacetate?(1.0 mg/kg, but not 0.3 mg/kg, iv) significantly reversed both subchronic ketamine- and subchronic PCP-induced NOR deficits.?Rapastinel Trifluoroacetate?also potentiated the atypical antipsychotic drug with antidepressant properties, lurasidone, to restore NOR in subchronic ketamine-treated mice.?Unlike ketamine,Rapastinel Trifluoroacetate?does not induce a declarative memory deficit in mice, and can prevent or reverse the ketamine-induced NOR deficit.?Further study is required to determine if these differences translate during clinical use of ketamine and rapastinel as fast acting antidepressant drugs and if rapastinel could have non-ionotropic effects as an add-on therapy with antipsychotic/antidepressant medications. |
别名 | Thr-Pro-Pro-Thr-NH2 Trifluoroacetate, GLYX-13 Trifluoroacetate |
分子量 | 527.49 |
分子式 | C20H32F3N5O8 |
CAS No. | 1435786-04-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (236.97 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8958 mL | 9.4789 mL | 18.9577 mL | 47.3943 mL |
5 mM | 0.3792 mL | 1.8958 mL | 3.7915 mL | 9.4789 mL | |
10 mM | 0.1896 mL | 0.9479 mL | 1.8958 mL | 4.7394 mL | |
20 mM | 0.0948 mL | 0.4739 mL | 0.9479 mL | 2.3697 mL | |
50 mM | 0.0379 mL | 0.1896 mL | 0.3792 mL | 0.9479 mL | |
100 mM | 0.019 mL | 0.0948 mL | 0.1896 mL | 0.4739 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rapastinel Trifluoroacetate 1435786-04-1 Membrane transporter/Ion channel Neuroscience NMDAR iGluR GLYX 13 inhibit GLYX13 GLYX-13 Inhibitor Rapastinel GLYX13 Trifluoroacetate Thr-Pro-Pro-Thr-NH2 Trifluoroacetate Ionotropic glutamate receptors GLYX-13 Trifluoroacetate GLYX 13 Trifluoroacetate inhibitor